Pneumococcal vaccination and revaccination of older adults.
about
Prospects for developing an effective particle-mediated DNA vaccine against influenza.Depletion of complement has distinct effects on the primary and secondary antibody responses to a conjugate of pneumococcal serotype 14 capsular polysaccharide and a T-cell-dependent protein carrier.Prevention strategies for herpes zoster and post-herpetic neuralgiaProprietary arabinogalactan extract increases antibody response to the pneumonia vaccine: a randomized, double-blind, placebo-controlled, pilot study in healthy volunteersRandomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients.Revisiting the B-cell compartment in mouse and humans: more than one B-cell subset exists in the marginal zone and beyond.Subversion of the B-cell compartment during parasitic, bacterial, and viral infectionsPneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination.Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept.Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines.Alterations in marginal zone macrophages and marginal zone B cells in old miceEffectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review.Recommendations for the use of the 23-valent polysaccharide pneumococcal vaccine in adults: a Belgian consensus report.Proteomic contributions to our understanding of vaccine and immune responses.Revaccination of adults with spinal cord injury using the 23-valent pneumococcal polysaccharide vaccine.Antibody response to pneumococcal vaccination as a function of preimmunization titer.Biology of immune responses to vaccines in elderly persons.Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects.Overview of vaccination policies for the elderly in Western European countries.Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.Pneumococcal vaccination among adults with chronic respiratory diseases: a historical overview.Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.Vaccination in the elderly: what can be recommended?Vaccines: A review of immune-based interventions to prevent and treat disease.BAFF receptor and TACI in B-1b cell maintenance and antibacterial responses.Evaluating the costs and benefits of pneumococcal vaccination in adults.Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study.An explosive outbreak of Streptococcus pneumoniae serotype-8 infection in a highly vaccinated residential care home, England, summer 2012.Age-Related Changes in Human Peripheral Blood IGH Repertoire Following Vaccination.Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease.Invasive pneumococcal infections in adult lung transplant recipients.Assignment of weight-based immunoglobulin G1 (IgG1) and IgG2 units in antipneumococcal reference serum lot 89-S(F) for pneumococcal polysaccharide serotypes 1, 4, 5, 7F, 9V, and 18CA 21-winter seasons retrospective study of antibody response after influenza vaccination in elderly (60-85 years old) and very elderly (>85 years old) institutionalized subjects.V(H)3 antibody response to immunization with pneumococcal polysaccharide vaccine in middle-aged and elderly persons.Public vaccination policy using an age-structured model of pneumococcal infection dynamics.Vaccination of older persons: a broader perspective.Adjuvant Probiotics and the Intestinal Microbiome: Enhancing Vaccines and Immunotherapy Outcomes.Pneumococcal vaccination and chronic respiratory diseases.Lifelong Maintenance of Oral Tolerance and Immunity Profiles in Mice Depends on Early Exposure to Antigen.
P2860
Q30380300-7D601908-1DE1-486E-A3AE-05D2D0CC4305Q33558995-0E640A77-F01A-48B5-9A7C-0D6E9AC29B61Q33562809-F10284A3-213B-407F-AE1A-A4169B305609Q34128683-80CE3A36-D264-4713-AEFA-D0A82BC4E8D8Q34430844-75DF8248-0068-41E5-ACFD-4F7B86E6BD17Q34495557-6A7120B6-96FA-40C0-8613-D89D1DECC52EQ35218945-0B77C1AC-35C8-4ABA-9956-686239E26522Q35783722-41C3FBAD-12F7-4090-9D1D-334D2661C235Q35874108-23D50DAF-3C16-4870-8B2E-BC8FE707EB6EQ36031285-AFEB0E82-CFA8-436E-9D7A-C135C702CFFDQ36083360-258F17B6-8978-4D93-890D-513653066132Q36168169-3A86BEC1-4F08-425B-842C-33E47F06F11BQ36204195-AE186FE2-A0B6-4181-98C0-0B1E792B65E9Q36406774-AD73B641-5D76-4F16-965D-7F213463A87DQ36464016-A2868651-DC18-4B2E-9B84-D57B002CF288Q36731011-5838C234-C270-426B-805E-32BD269B0246Q36731708-8F9FA5AF-1711-4956-B105-661F49D64AE7Q37150299-7CC2E358-9DD3-4313-B793-AF39EBD71403Q37197130-DBC946F1-3A62-47B7-AABD-BFAD7ED6EF31Q37538372-114119BF-A60B-40B8-B753-0EBFC5E9A065Q37910264-B2B8F701-B373-4B09-884A-8AC6B2A20196Q37981768-A5618106-76A0-4248-B857-6F7B0266DD78Q38082673-E0D238B1-AC5C-4B6F-B7CD-FB924618A306Q38220158-9FF26F85-CEF0-43DF-91CE-2576F6E123C1Q38364468-AB032056-8752-410C-BA6B-BDD64B00494AQ38472786-3F2B6805-5F60-477A-B7AC-CAF9F9C8FE49Q38966828-191BAC22-9AB2-493C-A25F-C23F20E6FA87Q39041235-556EC042-C2F7-47FF-B182-A03E9D549E55Q39116534-B1304197-0881-4A9F-8C14-49FEB1C6C063Q39587551-2EA0A25C-9D7C-4B34-8326-9B26A2C26306Q40469947-F0CBBBDA-C936-4626-90BC-8270E2DB229DQ40494158-898179CF-B49F-4B19-85F8-AE1D0168068BQ40773230-394A6393-43FF-408C-8F51-46342D560ED2Q41935331-C57ECFEB-C0C1-4E4A-BC2D-375D185BD86CQ42706531-B574FFEE-AB64-49CD-9BF2-A264AF6FDBF3Q44865385-831F911A-9F4F-49EA-A52F-0BD3609EC067Q46651028-C04BFD95-5788-4A53-96B4-4ED7EA6D3051Q47159439-DDCF2185-26BB-4288-866C-2804B6A9DAFDQ47162758-1EDA3772-E111-45F3-AE60-F5A57022217AQ48202683-7EF75F62-4A9E-43E1-A96A-95036C4E695A
P2860
Pneumococcal vaccination and revaccination of older adults.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pneumococcal vaccination and revaccination of older adults.
@ast
Pneumococcal vaccination and revaccination of older adults.
@en
Pneumococcal vaccination and revaccination of older adults.
@nl
type
label
Pneumococcal vaccination and revaccination of older adults.
@ast
Pneumococcal vaccination and revaccination of older adults.
@en
Pneumococcal vaccination and revaccination of older adults.
@nl
prefLabel
Pneumococcal vaccination and revaccination of older adults.
@ast
Pneumococcal vaccination and revaccination of older adults.
@en
Pneumococcal vaccination and revaccination of older adults.
@nl
P2093
P2860
P1476
Pneumococcal vaccination and revaccination of older adults.
@en
P2093
Andrew S Artz
Dan L Longo
William B Ershler
P2860
P304
P356
10.1128/CMR.16.2.308-318.2003
P407
P577
2003-04-01T00:00:00Z